Principal Financial Group
CPRX

Principal Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Principal Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.7M Sell
675,981
-7,697
-1% -$183K 0.01% 1032
2025
Q4 		$16M Buy
683,678
+44,558
+7% +$993K 0.01% 1030
2025
Q3 		$12.6M Buy
639,120
+15,153
+2% +$312K 0.01% 1154
2025
Q2 		$13.5M Buy
623,967
+6,461
+1% +$153K 0.01% 1084
2025
Q1 		$15M Buy
617,506
+17,018
+3% +$383K 0.01% 1023
2024
Q4 		$12.5M Buy
600,488
+24,535
+4% +$527K 0.01% 1159
2024
Q3 		$11.4M Sell
575,953
-63,273
-10% -$1.17M 0.01% 1196
2024
Q2 		$9.9M Sell
639,226
-10,214
-2% -$159K 0.01% 1266
2024
Q1 		$10.4M Buy
649,440
+71,133
+12% +$1.07M 0.01% 1283
2023
Q4 		$9.72M Buy
578,307
+478
+0.1% +$6.53K 0.01% 1299
2023
Q3 		$6.75M Sell
577,829
-3,161
-0.5% -$42.3K ﹤0.01% 1416
2023
Q2 		$7.81M Sell
580,990
-32,509
-5% -$468K 0.01% 1367
2023
Q1 		$10.2M Sell
613,499
-18,527
-3% -$306K 0.01% 1241
2022
Q4 		$11.8M Buy
632,026
+23,859
+4% +$367K 0.01% 1152
2022
Q3 		$7.8M Buy
608,167
+535,171
+733% +$6.34M 0.01% 1314
2022
Q2 		$512K Sell
72,996
-5,808
-7% -$42.6K ﹤0.01% 2056
2022
Q1 		$653K Sell
78,804
-39,876
-34% -$282K ﹤0.01% 2060
2021
Q4 		$803K Buy
+118,680
New +$780K ﹤0.01% 2028
2021
Q3 		– Sell
-11,205
Closed -$64K – 2585
2021
Q2 		$64K Sell
11,205
-9,496
-46% -$49K ﹤0.01% 2556
2021
Q1 		$95K Sell
20,701
-5,381
-21% -$21.4K ﹤0.01% 2426
2020
Q4 		$87K Sell
26,082
-10,106
-28% -$34K ﹤0.01% 2364
2020
Q3 		$107K Sell
36,188
-1,850
-5% -$7.23K ﹤0.01% 2258
2020
Q2 		$176K Buy
38,038
+10,517
+38% +$47.3K ﹤0.01% 2203
2020
Q1 		$106K Sell
27,521
-567
-2% -$2.33K ﹤0.01% 2115
2019
Q4 		$105K Sell
28,088
-1,713
-6% -$8.01K ﹤0.01% 2186
2019
Q3 		$158K Buy
29,801
+2,104
+8% +$11.2K ﹤0.01% 2159
2019
Q2 		$107K Buy
27,697
+14,700
+113% +$63.5K ﹤0.01% 2178
2019
Q1 		$66K Sell
12,997
-1,766
-12% -$5.19K ﹤0.01% 2172
2018
Q4 		$28K Sell
14,763
-3,615
-20% -$10.3K ﹤0.01% 2226
2018
Q3 		$69K Buy
18,378
+3,991
+28% +$12.5K ﹤0.01% 2251
2018
Q2 		$45K Buy
+14,387
New +$43.6K ﹤0.01% 2258
2018
Q1 		– Sell
-11,220
Closed -$44K – 2214
2017
Q4 		$44K Hold
11,220
– – ﹤0.01% 2223
2017
Q3 		$28K Sell
11,220
-1,874
-14% -$5.14K ﹤0.01% 2197
2017
Q2 		$36K Buy
+13,094
New +$27.3K ﹤0.01% 2245
2016
Q2 		– Sell
-12,745
Closed -$15K – 2173
2016
Q1 		$15K Hold
12,745
– – ﹤0.01% 2164
2015
Q4 		$31K Hold
12,745
– – ﹤0.01% 2173
2015
Q3 		$38K Buy
+12,745
New +$55K ﹤0.01% 2152

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Principal Financial Group's CPRX Position: Q1 2026 in Review

Principal Financial Group reduced its Catalyst Pharmaceutical (CPRX) stake by 1.1% in Q1 2026, selling an estimated $183K and leaving 675,981 shares worth $16.7M. The position accounts for 0.01% of the portfolio, ranked #1032.

Principal Financial Group first reported a position in CPRX in Q3 2015 and has held it in 37 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Principal Financial Group held 675,981 shares of Catalyst Pharmaceutical worth $16.7M as of Q1 2026.
  • Principal Financial Group sold 7,697 Catalyst Pharmaceutical shares in Q1 2026, an estimated $183K.
  • Catalyst Pharmaceutical made up 0.01% of Principal Financial Group's portfolio in Q1 2026, its #1032 holding.
  • Principal Financial Group first reported a position in Catalyst Pharmaceutical in Q3 2015 and has held it in 37 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.